- Home
- UTG vs NVCR Comparison
UTG vs NVCR Comparison
Compare UTG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTG
- NVCR
- Stock Information
- Founded
- UTG 2003
- NVCR 2000
- Country
- UTG United States
- NVCR Jersey
- Employees
- UTG N/A
- NVCR N/A
- Industry
- UTG Investment Managers
- NVCR Medical/Dental Instruments
- Sector
- UTG Finance
- NVCR Health Care
- Exchange
- UTG Nasdaq
- NVCR Nasdaq
- Market Cap
- UTG 2.8B
- NVCR 3.0B
- IPO Year
- UTG N/A
- NVCR 2015
- Fundamental
- Price
- UTG $31.73
- NVCR $32.10
- Analyst Decision
- UTG
- NVCR Buy
- Analyst Count
- UTG 0
- NVCR 5
- Target Price
- UTG N/A
- NVCR $33.40
- AVG Volume (30 Days)
- UTG 319.3K
- NVCR 1.8M
- Earning Date
- UTG 01-01-0001
- NVCR 10-30-2024
- Dividend Yield
- UTG 9.31%
- NVCR N/A
- EPS Growth
- UTG N/A
- NVCR N/A
- EPS
- UTG N/A
- NVCR N/A
- Revenue
- UTG N/A
- NVCR $577,738,000.00
- Revenue This Year
- UTG N/A
- NVCR $19.13
- Revenue Next Year
- UTG N/A
- NVCR $5.33
- P/E Ratio
- UTG N/A
- NVCR N/A
- Revenue Growth
- UTG N/A
- NVCR 14.63
- 52 Week Low
- UTG $23.24
- NVCR $11.70
- 52 Week High
- UTG $29.50
- NVCR $34.00
- Technical
- Relative Strength Index (RSI)
- UTG 35.91
- NVCR 69.73
- Support Level
- UTG $32.51
- NVCR $26.45
- Resistance Level
- UTG $33.25
- NVCR $34.00
- Average True Range (ATR)
- UTG 0.53
- NVCR 2.51
- MACD
- UTG -0.30
- NVCR 0.54
- Stochastic Oscillator
- UTG 9.31
- NVCR 88.10
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.